JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

By J. O’Shea, Robert M. Plenge. Immunity, 2012

1,107 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/0684150b9ad3e464a1ac7b365068ffc5b409c807

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. K. Futosi
2. Szabina Fodor
3. A. Mócsai

In Oncology

1. A. Mócsai

Citations in the corpus

• The JAK/STAT signaling pathway: from bench to clinic (2021, background): “T cells and myeloid cells may be activated and polarized into pathogenic phenotypes when the JAK/STAT pathway is aberrantly activated.(8,309) Importantly, preclinical data obtained from PD rat models confirmed that JAK inhibitors could significantly repress inflammatory cytokine production.”
• The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells (2017, background): “The most common adverse reaction is susceptibility to infections but opportunistic infections may also occur [6].”
• Neutrophil cell surface receptors and their intracellular signal transduction pathways (2013, background): “There is a wide diversity of JAK and STAT proteins utilized by the different cytokine receptors [135,136].”